We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioAlliance Pharma Submits Clinical Trial New Drug Application
News

BioAlliance Pharma Submits Clinical Trial New Drug Application

BioAlliance Pharma Submits Clinical Trial New Drug Application
News

BioAlliance Pharma Submits Clinical Trial New Drug Application

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioAlliance Pharma Submits Clinical Trial New Drug Application"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioAlliance Pharma SA has announced the submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency (AFSSaPS) and its approval by the Ethics Committee (Comité de Protection des Personnes).

This Phase I clinical trial will recruit its first subjects before end 2009. Patented until 2030, Fentanyl Lauriad® is based on the same muco-adhesive technology already validated with Loramyc®, BioAlliance already marketed drug. This sustained release new product is dedicated to the treatment of cancer chronic pain.

Furthermore, BioAlliance Pharma's shareholders were invited to attend the Extraordinary and Ordinary General Assembly Meeting on July 27th 2009 to vote on a new governance structure with a Board of Directors and corresponding changes of the by-laws.

A total of a 7,238,991 shares, representing 56.20% of existing shareholders, were attending or were represented at the Meeting. The resolution received 66.06% of the votes. As 66.67% were necessary to allow the structural changes, the current organization of the Supervisory Board and Management Board will be maintained.
Advertisement